Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001601830-22-000017
Filing Date
2022-04-28
Accepted
2022-04-28 16:01:36
Documents
15
Period of Report
2022-06-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A rxrx_proxystatement2022.htm DEF 14A 580801
2 image_0a.jpg GRAPHIC 125848
3 image_1a.jpg GRAPHIC 98963
4 image_2a.jpg GRAPHIC 569821
5 image_3a.jpg GRAPHIC 118473
6 img_2022proxystatementa.jpg GRAPHIC 1188031
7 img_aboutrecursiona.jpg GRAPHIC 1357933
8 img_proposal1a.jpg GRAPHIC 2261049
9 proxycard-01a.jpg GRAPHIC 875222
10 proxycard-02a.jpg GRAPHIC 757075
11 rec_proxydividerxv2a.jpg GRAPHIC 624790
12 rec_proxyxfinalxtocx1a.jpg GRAPHIC 302277
13 signaturea.jpg GRAPHIC 580233
14 vote-01a.jpg GRAPHIC 1965451
15 vote-02a.jpg GRAPHIC 1007138
  Complete submission text file 0001601830-22-000017.txt   16216778
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40323 | Film No.: 22866343
SIC: 2836 Biological Products, (No Diagnostic Substances)